novel therapeutics for metabolic and endocrine disorders.
Company profile
Ticker
VKTX
Exchange
Website
CEO
Brian Lian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Viking Therapeutics, PTY LTD ...
VKTX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
8-K
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
26 Mar 24
8-K
Other Events
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
8-K
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
1 Mar 24
424B5
Prospectus supplement for primary offering
27 Feb 24
8-K
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
27 Feb 24
S-8
Registration of securities for employees
7 Feb 24
Transcripts
VKTX
Earnings call transcript
2023 Q4
7 Feb 24
VKTX
Earnings call transcript
2023 Q3
25 Oct 23
VKTX
Earnings call transcript
2023 Q2
26 Jul 23
VKTX
Earnings call transcript
2023 Q1
26 Apr 23
VKTX
Earnings call transcript
2022 Q4
8 Feb 23
VKTX
Earnings call transcript
2022 Q3
27 Oct 22
VKTX
Earnings call transcript
2022 Q2
27 Jul 22
VKTX
Earnings call transcript
2022 Q1
28 Apr 22
VKTX
Earnings call transcript
2021 Q4
10 Feb 22
VKTX
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
Marianna Mancini
27 Mar 24
4
Brian Lian
27 Mar 24
4
GREG ZANTE
27 Mar 24
4
Brian Lian
4 Mar 24
4
Marianna Mancini
4 Mar 24
4
GREG ZANTE
4 Mar 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Brian Lian
9 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.19 mm | 37.19 mm | 37.19 mm | 37.19 mm | 37.19 mm | 37.19 mm |
Cash burn (monthly) | 10.78 mm | (no burn) | 9.09 mm | 7.65 mm | 6.55 mm | 5.56 mm |
Cash used (since last report) | 71.88 mm | n/a | 60.61 mm | 51.04 mm | 43.70 mm | 37.05 mm |
Cash remaining | -34.70 mm | n/a | -23.43 mm | -13.85 mm | -6.52 mm | 135.14 k |
Runway (months of cash) | -3.2 | n/a | -2.6 | -1.8 | -1.0 | 0.0 |
Institutional ownership, Q3 2023
73.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 186 |
Opened positions | 31 |
Closed positions | 42 |
Increased positions | 63 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 845.66 bn |
Total shares | 80.80 mm |
Total puts | 1.25 mm |
Total calls | 2.95 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 15.00 mm | $166.10 bn |
BLK Blackrock | 7.13 mm | $78.94 bn |
STT State Street | 6.41 mm | $70.97 bn |
Vanguard | 5.28 mm | $58.50 bn |
Viking Global Investors | 4.57 mm | $50.63 bn |
LGND Ligand Pharmaceuticals, Inc. - Ordinary Shares | 3.62 mm | $55.83 mm |
Alliancebernstein | 3.55 mm | $39.30 bn |
American Century Companies | 2.20 mm | $24.38 bn |
Balyasny Asset Management | 2.12 mm | $23.49 bn |
Geode Capital Management | 2.03 mm | $22.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 83.34 | 16,610 | 1.38 mm | 207,361 |
27 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 223,971 |
27 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 83.34 | 16,610 | 1.38 mm | 363,565 |
27 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 380,175 |
27 Mar 24 | Lian Brian | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 83.34 | 153,948 | 12.83 mm | 2,266,453 |
27 Mar 24 | Lian Brian | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 221,667 | 0.00 | 2,420,401 |
1 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 85.22 | 20,093 | 1.71 mm | 192,304 |
1 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 212,397 |
1 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 85.22 | 16,958 | 1.45 mm | 348,508 |
1 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 365,466 |
News
Market Whales and Their Recent Bets on VKTX Options
18 Apr 24
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
15 Apr 24
Viking Therapeutics's Options: A Look at What the Big Money is Thinking
9 Apr 24
10 Health Care Stocks Whale Activity In Today's Session
4 Apr 24
10 Health Care Stocks Whale Activity In Today's Session
3 Apr 24
Press releases
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
17 Apr 24
Thinking about trading options or stock in Micron Technology, Apple, Viking Therapeutics, Marvell Technology, or Vertiv Holdings?
1 Apr 24
Thinking about trading options or stock in NVIDIA, Vale, Viking Therapeutics, GigaCloud Technology, or Crowdstrike Holdings?
27 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
26 Mar 24